A phase 2 study of vorinostat in acute myeloid leukemiaÉlise Schaefer, S. D. Gore, Arturo Loaiza‐Bonilla et al.|Haematologica|2009Cited by 119
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp>‐medicare analysisSikander Ailawadhi, Asher Chanan‐Khan, Ryan D. Frank et al.|Cancer Medicine|2017Cited by 88
Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin’s Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809Richard I. Fisher, Thomas P. Miller, Bruce W. Dana et al.|Journal of Clinical Oncology|2000Cited by 81
Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparitiesSikander Ailawadhi, Asher Chanan‐Khan, Ryan D. Frank et al.|Cancer|2018Cited by 55
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosisTania Jain, Jeanne Palmer, Katie L. Kunze et al.|Bone Marrow Transplantation|2018Cited by 46